肠道菌群在结直肠癌早期诊断和预后评估中的研究进展

doi:10.19586/j.2095-2341.2025.0035

生物技术进展 ›› 2025, Vol. 15 ›› Issue (5): 839-844.DOI: 10.19586/j.2095-2341.2025.0035

肠道菌群在结直肠癌早期诊断和预后评估中的研究进展

李峻宇¹(), 王润泽²^,³(), 张黄子怡¹, 夏超¹, 仪杨¹, 谢飞¹(), 朱锡德³()

^1.北京工业大学化学与生命科学学院，北京 100124
^2.山东第二医科大学临床医学院，山东潍坊，261053
^3.临沂市人民医院神经外科，山东临沂 276000

收稿日期:2025-03-15 接受日期:2025-05-09 出版日期:2025-09-25 发布日期:2025-11-11
通讯作者: 谢飞,朱锡德
作者简介:李峻宇 E-mail: ljyxxx008@126.com
王润泽 E-mail: 769258221@qq.com第一联系人：李峻宇和王润泽为共同第一作者。
基金资助:
军委后勤保障部开放研究重点项目(BHJ17L018)

Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer

Junyu LI¹(), Runze WANG²^,³(), Ziyi ZHANG-HUANG¹, Chao XIA¹, Yang YI¹, Fei XIE¹(), Xide ZHU³()

^1.College of Chemistry and Life Science，Beijing University of Technology，Beijing 100124，China
^2.School of Clinical Medicine，Shandong Second Medical University，Shandong Weifang 261053，China
^3.Department of Neurosurgery，Linyi People's Hospital，Shandong Linyi 276000，China

Received:2025-03-15 Accepted:2025-05-09 Online:2025-09-25 Published:2025-11-11
Contact: Fei XIE,Xide ZHU

摘要/Abstract

摘要：

结直肠癌是全球常见的恶性肿瘤之一，其发病率和死亡率均居高不下。早期筛查和诊断对于降低结直肠癌的死亡率至关重要。近年来，研究表明肠道菌群的组成和功能变化与结直肠癌的发生、发展密切相关。综述了肠道菌群在结直肠癌早期诊断和预后评估中的研究进展，探讨了肠道菌群作为生物标志物的潜力以及调节肠道菌群对结直肠癌治疗的潜在影响，旨在为结直肠癌的早期筛查、诊断和治疗提供新的思路和方法。

关键词: 肠道菌群, 结直肠癌, 早期诊断, 预后评估, 生物标志物

Abstract:

Colorectal cancer is one of the most common malignancies worldwide， with persistently high incidence and mortality rates. Early screening and diagnosis are crucial for reducing colorectal cancer mortality. In recent years， studies have shown that alterations in the composition and function of gut microbiota are closely associated with the occurrence and development of colorectal cancer. This article reviewed the research progress of gut microbiota in early diagnosis and prognostic evaluation of colorectal cancer， explored the potential of gut microbiota as biomarkers， and discussed the impact of modulating gut microbiota on colorectal cancer treatment， aiming to provide new perspectives and methods for early screening， diagnosis， and treatment of colorectal cancer.

Key words: gut microbiota, colorectal cancer, early diagnosis, prognostic evaluation, biomarker

中图分类号:

Q933

李峻宇, 王润泽, 张黄子怡, 夏超, 仪杨, 谢飞, 朱锡德. 肠道菌群在结直肠癌早期诊断和预后评估中的研究进展[J]. 生物技术进展, 2025, 15(5): 839-844.

Junyu LI, Runze WANG, Ziyi ZHANG-HUANG, Chao XIA, Yang YI, Fei XIE, Xide ZHU. Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer[J]. Current Biotechnology, 2025, 15(5): 839-844.

参考文献 44

[1]	SUNG H, FERLAY J, SIEGEL R L, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J. Clin., 2021, 71(3): 209-249.
[2]	LIU S C, ZHANG H. Early diagnostic strategies for colorectal cancer[J]. World J. Gastroenterol., 2024, 30(33): 3818-3822.
[3]	SIEGEL R L, WAGLE N S, CERCEK A, et al.. Colorectal cancer statistics, 2023[J]. CA A Cancer J. Clin., 2023, 73(3): 233-254.
[4]	WIRBEL J, PYL P T, KARTAL E, et al.. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat. Med., 2019, 25(4): 679-689.
[5]	YACHIDA S, MIZUTANI S, SHIROMA H, et al.. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer[J]. Nat. Med., 2019, 25(6): 968-976.
[6]	LIU N N, JIAO N, TAN J C, et al.. Multi-Kingdom microbiota analyses identify bacterial-fungal interactions and biomarkers of colorectal cancer across cohorts[J]. Nat. Microbiol., 2022, 7(2): 238-250.
[7]	THOMAS A M, MANGHI P, ASNICAR F, et al.. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation[J]. Nat. Med., 2019, 25(4): 667-678.
[8]	XU C, FAN L, LIN Y, et al.. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization[J/OL]. Gut Microbes, 2021, 13(1): 1980347[2025-05-09]. .
[9]	COKER O O, LIU C, WU W K K, et al.. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers[J/OL]. Microbiome, 2022, 10(1): 35[2025-05-09]. .
[10]	LOPÈS A, BILLARD E, CASSE A H, et al.. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer[J]. Int. J. Cancer, 2020, 146(11): 3147-3159.
[11]	ULGER TOPRAK N, YAGCI A, GULLUOGLU B M, et al.. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer[J]. Clin. Microbiol. Infect., 2006, 12(8): 782-786.
[12]	CHANG C W, LEE H C, LI L H, et al.. Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil/oxaliplatin-induced toxicity in colorectal cancer[J/OL]. Int. J. Mol. Sci., 2020, 21(2): 386[2025-05-09]. .
[13]	WANG N, FANG J Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer[J]. Trends Microbiol., 2023, 31(2): 159-172.
[14]	YANG Y, WENG W, PENG J, et al.. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-κB, and up-regulating expression of microRNA-21[J]. Gastroenterology, 2017, 152(4): 851-866.
[15]	CAO Y, WANG Z, YAN Y, et al.. Enterotoxigenic bacteroidesfragilis promotes intestinal inflammation and malignancy by inhibiting exosome-packaged miR-149-3p [J]. Gastroenterology, 2021, 161(5): 1552-1566.
[16]	PLEGUEZUELOS-MANZANO C, PUSCHHOF J, ROSENDAHL H A, et al.. Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli [J]. Nature, 2020, 580(7802): 269-273.
[17]	SALESSE L, LUCAS C, HOANG M H T, et al.. Colibactin-producing Escherichia coli induce the formation of invasive carcinomas in a chronic inflammation-associated mouse model[J/OL]. Cancers, 2021, 13(9): 2060[2025-05-09]. .
[18]	CHEN H, TONG T, LU S Y, et al.. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis[J]. Cell Metab., 2023, 35(4): 651-666.
[19]	GUR C, IBRAHIM Y, ISAACSON B, et al.. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack[J]. Immunity, 2015, 42(2): 344-355.
[20]	GUR C, MAALOUF N, SHHADEH A, et al.. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1[J/OL]. OncoImmunology, 2019, 8(6): e1581531[2025-05-09]. .
[21]	HU L, LIU Y, KONG X, et al.. Fusobacterium nucleatum facilitates M2 macrophage polarization and colorectal carcinoma progression by activating TLR4/NF-κB/S 100A9 cascade[J/OL]. Front. Immunol., 2021, 12: 658681[2025-05-09]. .
[22]	CHEN T, LI Q, WU J, et al.. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism[J]. Cancer Immunol. Immunother., 2018, 67(10): 1635-1646.
[23]	GEIS A L, HOUSSEAU F. Procarcinogenic regulatory T cells in microbial-induced colon cancer[J/OL]. Oncoimmunology, 2016, 5(4): e1118601[2025-05-09]. .
[24]	DZIUBAŃSKA-KUSIBAB P J, BERGER H, BATTISTINI F, et al.. Colibactin DNA-damage signature indicates mutational impact in colorectal cancer[J]. Nat. Med., 2020, 26(7): 1063-1069.
[25]	JANS M, KOLATA M, BLANCKE G, et al.. Colibactin-driven colon cancer requires adhesin-mediated epithelial binding[J]. Nature, 2024, 635(8038): 472-480.
[26]	TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J/OL]. Med. Sci. 2018, 6(2): 31[2025-05-09]. .
[27]	JIANG S S, XIE Y L, XIAO X Y, et al.. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer[J]. Cell Host Microbe, 2023, 31(5): 781-797.
[28]	NOSHO K, SUKAWA Y, ADACHI Y, et al.. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer[J]. World J. Gastroenterol., 2016, 22(2): 557-566.
[29]	PARK H E, KIM J H, CHO N Y, et al.. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma[J]. Virchows Arch., 2017, 471(3): 329-336.
[30]	XIE Y, JIAO X, ZENG M, et al.. Clinical significance of Fusobacterium nucleatum and microsatellite instability in evaluating colorectal cancer prognosis[J]. Cancer Manag. Res., 2022, 14: 3021-3036.
[31]	AMITAY E L, KRILAVICIUTE A, BRENNER H. Systematic review: gut microbiota in fecal samples and detection of colorectal neoplasms[J]. Gut Microbes, 2018, 9(4): 293-307.
[32]	CONDE-PÉREZ K, AJA-MACAYA P, BUETAS E, et al.. The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis[J]. Mol. Oncol., 2024, 18(5): 1093-1122.
[33]	MIMA K, NISHIHARA R, QIAN Z R, et al.. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12): 1973-1980.
[34]	WU S, JRHEE K, ALBESIANO E, et al.. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses[J]. Nat. Med., 2009, 15(9): 1016-1022.
[35]	PNOUGAYRÈDE J, HOMBURG S, TAIEB F, et al.. Escherichia coli induces DNA double-strand breaks in eukaryotic cells[J]. Science, 2006, 313(5788): 848-851.
[36]	XU Y, ZHAO J, MA Y, et al.. The microbiome types of colorectal tissue are potentially associated with the prognosis of patients with colorectal cancer[J/OL]. Front. Microbiol., 2023, 14: 1100873[2025-05-09]. .
[37]	O'KEEFE S J D. Diet, microorganisms and their metabolites, and colon cancer[J]. Nat. Rev. Gastroenterol. Hepatol., 2016, 13(12): 691-706.
[38]	JONES B V, BEGLEY M, HILL C, et al.. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome[J]. Proc. Natl. Acad. Sci. USA, 2008, 105(36): 13580-13585.
[39]	CHEN G, REN Q, ZHONG Z, et al.. Exploring the gut microbiome's role in colorectal cancer: diagnostic and prognostic implications[J/OL]. Front. Immunol., 2024, 15: 1431747[2025-05-09]. .
[40]	WU Y, ZHUANG J, ZHOU J, et al.. Prediction model of colorectal cancer (CRC) lymph node metastasis based on intestinal bacteria[J]. Clin. Transl. Oncol., 2023, 25(6): 1661-1672.
[41]	LIANG Q, CHIU J, CHEN Y, et al.. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin. Cancer Res., 2017, 23(8): 2061-2070.
[42]	BAXTER N T, RUFFIN M T, ROGERS M A M, et al.. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions[J/OL]. Genome Med., 2016, 8(1): 37[2025-05-09]. .
[43]	HUANG Z, HUANG X, HUANG Y, et al.. Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model[J/OL]. Microbiol. Spectr., 2024, 12(5): e0272023[2025-05-09]. .
[44]	MA M, ZHENG Z, LI J, et al.. Association between the gut microbiota, inflammatory factors, and colorectal cancer: evidence from Mendelian randomization analysis[J/OL]. Front. Microbiol., 2024, 15: 1309111[2025-05-09]. .

肠道菌群在结直肠癌早期诊断和预后评估中的研究进展

Research Progress on the Role of Gut Microbiota in Early Diagnosis and Prognostic Evaluation of Colorectal Cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 44

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘晓雅, 张硕珉, 郑鹏, 马睿, 张朝军. DBNDD1基因在结直肠癌进展过程中的作用与机制研究[J]. 生物技术进展, 2025, 15(4): 726-734.
[2]	罗焱, 洪琪, 梁乐怡, 余诗玥, 陈琼霞, 韩晓芳, 镇鸿燕. WIPI2基因过表达慢病毒载体的构建及表达[J]. 生物技术进展, 2025, 15(1): 135-141.
[3]	布尔兰·叶尔肯别克, 郭文佳, 董晓刚. 骨膜蛋白在肿瘤微环境中的作用研究进展[J]. 生物技术进展, 2024, 14(2): 205-210.
[4]	徐婷, 沈佳豪, 赵康, 黄鹭, 董恩惠, 曾可心, 卞新为, 季明辉, 许勤. 基于瘤胃球菌微生物群丰度构建疾病类型预测的肠道菌群标签[J]. 生物技术进展, 2024, 14(2): 323-330.
[5]	曹克浩, 朱军利, 何华山, 徐慰倬. 专利法第四次修改对生物技术专利申请和产业发展的影响[J]. 生物技术进展, 2023, 13(5): 663-670.
[6]	曹海涛, 朱静, 马云鹏, 崔兴华. 机器学习在肠道菌群宿主表型预测中的应用[J]. 生物技术进展, 2023, 13(5): 671-680.
[7]	杜琳琳, 谢飞, 马雪梅. SALL4的促癌功能及治疗意义[J]. 生物技术进展, 2023, 13(5): 704-711.
[8]	安外尔·约麦尔阿卜拉, 孙莉莉, 布尔兰·叶尔肯别克, 郭文佳. Piezo1在癌症中的作用研究进展[J]. 生物技术进展, 2023, 13(5): 712-717.
[9]	曹海涛, 朱静, 曾海波, 刘彦辰. 基于加权平均的肠道菌群特征筛选和疾病预测模型研究[J]. 生物技术进展, 2023, 13(5): 798-806.
[10]	白亮, 黄鹤, 王苹. 合成生物学在治疗代谢性疾病中的研究进展[J]. 生物技术进展, 2023, 13(3): 383-389.
[11]	朱兴墅, 黄军杰, 翁才明, 刘旺武, 陈永元, 陈惠燕, 赵虎, 王瑜, 林承志. 基于生物信息学分析林奇综合征相关结直肠癌关键Hub基因的筛选与功能富集分析[J]. 生物技术进展, 2023, 13(2): 291-297.
[12]	刘梓嘉, 姜雪, 仪杨, 王濛, 马晨, 宋怡菲, 谢飞. 氢气与肠道菌群的关系研究进展[J]. 生物技术进展, 2022, 12(6): 847-852.
[13]	于敏, 王敏, 魏延焕, 刘毅毅. SARS-CoV-2病毒感染潜在关键分子生物标志物及免疫浸润特征分析[J]. 生物技术进展, 2022, 12(5): 760-768.
[14]	王濛, 仪杨, 孙梦婷, 刘梓嘉, 姜雪, 马晨, 宋怡菲, 谢飞. 富氢水和富氢生理盐水生物医学研究进展——动物实验[J]. 生物技术进展, 2022, 12(3): 332-343.
[15]	武丽娜, 彭小忠, 鲁重美. 长链非编码RNA ZFAS1在结直肠癌中的表达及生物学功能[J]. 生物技术进展, 2022, 12(3): 427-435.